Zobrazeno 1 - 10
of 153
pro vyhledávání: '"B Mlineritsch"'
Autor:
B. Mlineritsch, Catharina Arnold-Schrauf, Johannes Andel, Birgit Gruenberger, Klaus Wilthoner, Robert Trondl, Leopold Oehler, Hans-Joerg Neumann, Thomas Winder, Andreas L. Petzer, Kathrin Philipp-Abbrederis, Wolfgang Eisterer, Armin Gerger, Petra Pichler, Gerald W. Prager, Angela Djanani, Friedrich Laengle, Markus Korger, Martin Pecherstorfer, Sonja Heibl, Eva Hubmann, Ewald Wöll, Thamer Sliwa
Publikováno v:
European journal of cancer (Oxford, England : 1990). 143
Background Pancreatic cancer (PC) ranks among the deadliest malignancies worldwide. In the MPACT study, first-line nab-paclitaxel plus gemcitabine (nab-P/G) demonstrated activity (median overall survival [OS], 8.7 months) and tolerability in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ade288fb7b3a4cbcd2b31c4f8611e02
https://pubmed.ncbi.nlm.nih.gov/33296830
https://pubmed.ncbi.nlm.nih.gov/33296830
Autor:
G Rinnerthaler, SP Gampenrieder, A Petzer, R Pusch, M Fridrik, D Rossmann, M Balic, D Egle, H Rumpold, C Singer, R Bartsch, T Melchardt, H Ulmer, B Mlineritsch, R Greil
Publikováno v:
Cancer Research. 78:OT2-07
Background: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with a poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy is approved for TNBC so far and cytotoxic age
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d8cc7dd3912f12fd5022d0820cbab16
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-11
https://doi.org/10.1158/1538-7445.sabcs17-ot2-07-11
Autor:
G Rinnerthaler, SP Gampenrieder, D Voskova, A Petzer, M Hubalek, E Petru, B Hartmann, J Andel, M Balic, T Melchardt, H Ulmer, B Mlineritsch, R Greil
Publikováno v:
Cancer Research. 77:P5-15
Background: Capecitabine is a well-established treatment option in HER2-negative advanced breast cancer (ABC) patients. Bendamustine is a generally well tolerated cytotoxic drug. Since bendamustine has already shown anticancer activity in ABC we eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b179fd0087ebcf639697d7c9b9a1e1a9
https://doi.org/10.1158/1538-7445.sabcs16-p5-15-13
https://doi.org/10.1158/1538-7445.sabcs16-p5-15-13
Autor:
M, Gnant, M, Filipits, R, Greil, H, Stoeger, M, Rudas, Z, Bago-Horvath, B, Mlineritsch, W, Kwasny, M, Knauer, C, Singer, R, Jakesz, P, Dubsky, F, Fitzal, R, Bartsch, G, Steger, M, Balic, S, Ressler, J W, Cowens, J, Storhoff, S, Ferree, C, Schaper, S, Liu, C, Fesl, T O, Nielsen, Peggy, Tsang
Publikováno v:
Annals of Oncology. 25:339-345
PAM50 is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and generate a Risk of Recurrence (ROR) score. It has been developed to be carried out in qualified routine hospital pathology laboratories.One thousand four hundre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5269753483edc4444907447a5af6b89
https://doi.org/10.1093/annonc/mdt494
https://doi.org/10.1093/annonc/mdt494
Autor:
B. Mlineritsch, Michael Gnant, Michael Stierer, Michael Seifert, Marija Balic, Georg Pfeiler, Christian Fesl, Raimund Jakesz, Werner Kwasny, Florian Fitzal, Hellmut Samonigg, Herbert Stöger, Günther G. Steger, Richard Greil, Peter Dubsky
Publikováno v:
British Journal of Cancer
Background: We investigated whether body mass index (BMI) can be used as a predictive parameter indicating patients who benefit from extended aromatase inhibitor (AI) treatment. Methods: The ABCSG-6a trial re-randomised event-free postmenopausal horm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da0559d613c5aa56b254f35f0059fb2b
https://doi.org/10.1038/bjc.2013.367
https://doi.org/10.1038/bjc.2013.367
Autor:
B. Mlineritsch, Michael Gnant, Werner Kwasny, Ferdinand Ploner, Christian F. Singer, Martin Moik, Michael Seifert, Georg Pfeiler, P. Sandbichler, Richard Greil, Peter Dubsky, Friedrich Hofbauer, U Selim, Hellmut Samonigg, Florian Fitzal, Marija Balic, Christian Fesl, Raimund Jakesz, Herbert Stöger, Günther G. Steger, K Renner
Publikováno v:
British Journal of Cancer
Background: There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship between BMI and the efficacy of tamoxifen is conflicting. We investigated the impact of BMI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e0065f0a697c9a31c5628e7695f5e1a
https://doi.org/10.1038/bjc.2013.114
https://doi.org/10.1038/bjc.2013.114
Autor:
C Gouy, P Wolfrum-Ristau, Thorsten Fischer, H Koch, G Bogner, C Fazelnia, B Mlineritsch, C Schönlieb, Cornelia Kronberger
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc6602c2bdc36f75400869cd14fe13e6
https://doi.org/10.1055/s-0036-1579591
https://doi.org/10.1055/s-0036-1579591
Autor:
Johannes Andel, Thamer Sliwa, Christoph Tinchon, B. Mlineritsch, Michael Seifert, Werner Kwasny, Petra Pichler, Christian Marth, Günther G. Steger, Edgar Petru, Daniel Egle, A. Galid, Richard Greil, R. Ruckser, Alois Lang, Andreas L. Petzer, Rupert Bartsch, Ferdinand Haslbauer, Christian F. Singer, T. Kuehr
Publikováno v:
European Journal of Cancer. 92:S97
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0551c8c16b01b4eb2ff34734c1eceb3e
https://doi.org/10.1016/s0959-8049(18)30519-7
https://doi.org/10.1016/s0959-8049(18)30519-7
Autor:
Michael Gnant, B. Mlineritsch, Michael A. Fridrik, R. Kolb, Hubert Hausmaninger, Michael Seifert, Karin Haider, Michael Stierer, Ernst Kubista, Günther G. Steger, P. Steindorfer, Raimund Jakesz, H. Samonigg, G. Tschurtschenthaler, Ferdinand Ploner
Publikováno v:
Oncology Research and Treatment. 26:115-119
A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6b44d3ae8a0aa79b93e79e805e3c2f3
https://doi.org/10.1159/000069831
https://doi.org/10.1159/000069831
Autor:
Alexandra Kaider, Michael A. Fridrik, Hartmut Schmidt, Martin Pecherstorfer, Ch. Kopf, Heinz Ludwig, B. Mlineritsch, H. Samonigg, R. Moser, D Nitsche, Hubert Hausmaninger
Publikováno v:
European Journal of Cancer. 35:380-385
5-Fluorouracil (5-FU) remains the mainstay of treatment for advanced colorectal carcinoma, although response rates are generally less than 20%. Improved therapeutic efficacy has been reported using biochemical modulation of 5-FU by leucovorin (LV) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18a5708bcc966514210afc8f01ec617e
https://doi.org/10.1016/s0959-8049(98)00397-9
https://doi.org/10.1016/s0959-8049(98)00397-9